Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
September 18 2017 - 4:15PM
Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a
clinical-stage pharmaceutical company discovering and developing
targeted therapeutics in disease areas of inflammation and
immuno-oncology, announced today that David Main, Aquinox President
& CEO, will present a corporate overview at the upcoming
2017 Cantor Fitzgerald Global Healthcare
Conference in New York, NY on
Monday, September
25th, 2017 at
10:20 AM Eastern
Time.
A live audio webcast and archive of the event will be available
at: http://wsw.com/webcast/cantor6/aqxp/
To ensure a timely connection to the webcast, it is recommended
that users register at least 15 minutes prior to the scheduled
start time. An archived version of the webcast will also be
available on the Investor Relations page of the Aquinox website.
The corporate overview being presented will be available following
the presentation at www.aqxpharma.com.
About Aquinox
Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage
pharmaceutical company discovering and developing targeted
therapeutics in disease areas of inflammation and immuno-oncology.
Our primary focus is anti-inflammatory product candidates targeting
SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key
regulator of an important cellular signaling pathway in immune
cells, known as the PI3K pathway. Aquinox's lead drug candidate,
AQX-1125, is a small molecule activator of SHIP1 suitable for oral,
once daily dosing. In September 2016, we began enrolling patients
in a Phase 3 clinical trial of AQX-1125 in our lead indication,
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other
indications are under consideration for future investigation.
Aquinox has a broad intellectual property portfolio and pipeline of
preclinical drug candidates that activate SHIP1. For more
information, please visit www.aqxpharma.com.
Investor Contact
Info:
Brendan
PayneAssociate Director, Investor
Relations Aquinox Pharmaceuticals,
Inc.604.901.3019ir@aqxpharma.com
Gitanjali OgawaVice
President The Trout
Group
646-378-2949
Gogawa@troutgroup.com
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From Apr 2023 to Apr 2024